JarandJ, LevinA, ZhangL, et al.Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease. Clin Infect Dis, 2011; 52:565–571; doi: 10.1093/CID/CIQ237
2.
ShahrakiAH, MirsaiediM. Phage therapy for Mycobacterium abscessus and strategies to improve outcomes. Microorganisms, 2021; 9(3):596; doi: 10.3390/microorganisms9030596
3.
CohenA, MathiasenVD, SchonT, et al.The global prevalence of latent tuberculosis: A systematic review and meta-analysis. Eur Respir J, 2019; 54(3); doi: 10.1183/13993003.00655-2019
4.
BradburyA, PluckthunA. Reproducibility: Standardize antibodies used in research. Nature, 2015; 518(7537):27–29; doi: 10.1038/518027a
5.
FleishmanSJ, WhiteheadTA, EkiertDC, et al.Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science, 2011; 332(6031):816–821; doi: 10.1126/science.1202617
6.
StrauchEM, FleishmanSJ, BakerD. Computational design of a pH-sensitive IgG binding protein. Proc Natl Acad Sci U S A, 2014; 111(2):675–680; doi: 10.1073/pnas.1313605111
7.
SafirMC, BhavnaniSM, SloverCM, et al.Antibacterial drug development: A new approach is needed for the field to survive and thrive. Antibiotics (Basel), 2020; 9(7); doi: 10.3390/antibiotics9070412
8.
ZurawskiDV, McLendonMK. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics (Basel), 2020; 9(4); doi: 10.3390/antibiotics9040155
